Vanda Pharmaceuticals (VNDA) Fundamental Analysis: Revenue, Earnings & Valuation

1.77 / 10

Underperform

Fundamental analysis rates VNDA as Underperform (1.8/10). Strengths include a low cost‑of‑sales ratio (6.04%) and strong interest coverage (35.1x). However, high current‑liabilities proportion (89.7%) and modest revenue growth (~8.7% YoY) create defensive concerns.

Analysis Checks(5/10)

Revenue-MV

Value-0.35

Score2/3

Weight33.74%

1M Return4.88%

Total operating revenue (YoY growth rate %)

Value8.72

Score1/3

Weight-2.08%

1M Return-0.38%

Inventory turnover ratio

Value7.29

Score2/3

Weight-6.06%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value89.74

Score1/3

Weight-8.49%

1M Return-1.69%

PB-ROE

Value-0.01

Score1/3

Weight42.98%

1M Return7.56%

Long-term debt to working capital ratio (%)

Value0.08

Score2/3

Weight-1.88%

1M Return-0.35%

Interest coverage ratio (EBIT / Interest expense) (%)

Value35.11

Score2/3

Weight-6.17%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value8.72

Score1/3

Weight-1.64%

1M Return-0.30%

Cost of sales ratio (%)

Value6.04

Score3/3

Weight1.54%

1M Return0.26%

Asset-MV

Value-0.55

Score1/3

Weight48.06%

1M Return6.31%

Is VNDA undervalued or overvalued?

VNDA scores 1.77/10 on fundamentals and holds a Premium valuation at present. Backed by its -50.93% ROE, -102.02% net margin, -1.85 P/E ratio, 1.25 P/B ratio, and -1033.33% earnings growth, these metrics solidify its Underperform investment rating.